Covered recipient · General Payments record
MANZOOR QADIR
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
General Payments · PY2018–2024
$2,014.40
- Reported across 78 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $590.99 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $248.12 | 9 |
| Janssen Biotech, Inc. | $117.13 | 2 |
| INTERCEPT PHARMACEUTICALS, INC. | $116.83 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $23.82 | 1 |
| Phathom Pharmaceuticals, Inc. | $20.17 | 1 |
| Ardelyx, Inc. | $17.70 | 1 |
| Gilead Sciences, Inc. | $17.35 | 1 |
| IRONWOOD PHARMACEUTICALS, INC | $15.60 | 1 |
| AIMMUNE THERAPEUTICS, INC. | $14.27 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $18.14 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105330776 | CMS |
| ABBVIE INC. | $16.71 | 03/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105330780 | CMS |
| ABBVIE INC. | $10.79 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105330784 | CMS |
| ABBVIE INC. | $120.80 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105330787 | CMS |
| ABBVIE INC. | $17.06 | 07/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105330791 | CMS |
| ABBVIE INC. | $4.50 | 08/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105330796 | CMS |
| ABBVIE INC. | $23.77 | 08/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105330800 | CMS |
| ABBVIE INC. | $7.54 | 10/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105330804 | CMS |
| ABBVIE INC. | $28.81 | 11/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105330808 | CMS |
| AIMMUNE THERAPEUTICS, INC. | $14.27 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147002298 | CMS |
| Ardelyx, Inc. | $17.70 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146701928 | CMS |
| Gilead Sciences, Inc. | $17.35 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133782186 | CMS |
| Intercept Pharmaceuticals, Inc. | $116.83 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1113638247 | CMS |
| IRONWOOD PHARMACEUTICALS, INC | $15.60 | 07/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153756569 | CMS |
| Janssen Biotech, Inc. | $17.58 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078525214 | CMS |
| Janssen Biotech, Inc. | $99.55 | 10/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078525198 | CMS |
| Phathom Pharmaceuticals, Inc. | $20.17 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151112524 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $23.82 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137657316 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.